AG
RYTM icon

Algert Global’s Rhythm Pharmaceuticals RYTM Stock Holding History

Algert Global’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09M Sell
58,513
-29,737
-34% -$2.89M 0.08% 437
2025
Q4 		$9.45M Sell
88,250
-52,034
-37% -$5.52M 0.15% 214
2025
Q3 		$14.2M Buy
140,284
+80,065
+133% +$7.43M 0.24% 97
2025
Q2 		$3.81M Sell
60,219
-1,242
-2% -$76K 0.08% 421
2025
Q1 		$3.26M Buy
61,461
+19,910
+48% +$1.1M 0.08% 428
2024
Q4 		$2.33M Sell
41,551
-12,620
-23% -$697K 0.05% 552
2024
Q3 		$2.84M Sell
54,171
-49,961
-48% -$2.39M 0.08% 439
2024
Q2 		$4.28M Buy
104,132
+35,084
+51% +$1.4M 0.14% 220
2024
Q1 		$2.99M Buy
69,048
+40,245
+140% +$1.76M 0.12% 295
2023
Q4 		$1.32M Sell
28,803
-4,610
-14% -$145K 0.05% 541
2023
Q3 		$766K Sell
33,413
-25,680
-43% -$575K 0.04% 626
2023
Q2 		$974K Buy
+59,093
New +$1.07M 0.04% 668
2021
Q1 		– Sell
-12,080
Closed -$359K – 517
2020
Q4 		$359K Buy
+12,080
New +$307K 0.1% 275

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Algert Global's RYTM Position: Q1 2026 in Review

Algert Global reduced its Rhythm Pharmaceuticals (RYTM) stake by 34% in Q1 2026, selling an estimated $2.89M and leaving 58,513 shares worth $5.09M. The position accounts for 0.08% of the portfolio, ranked #437.

Algert Global first reported a position in RYTM in Q4 2020 and has held it in 13 quarters since. The position peaked at $14.2M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Algert Global held 58,513 shares of Rhythm Pharmaceuticals worth $5.09M as of Q1 2026.
  • Algert Global sold 29,737 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $2.89M.
  • Rhythm Pharmaceuticals made up 0.08% of Algert Global's portfolio in Q1 2026, its #437 holding.
  • Algert Global first reported a position in Rhythm Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
  • Algert Global's Rhythm Pharmaceuticals position peaked at $14.2M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.